

### **A USD 2 million drug**

Novartis has received U.S. approval for its gene therapy Zolgensma for the treatment of spinal muscular atrophy, the leading genetic cause of death in infants. The company priced the one-time treatment at a record USD 2 million. Novartis said it was offering health insurers the option of installment payments for Zolgensma.